Screen Reader Mode Icon Check SCREEN READER MODE to make this survey compatible with screen readers. JM Quiz Proposal April 2021 Question Title * 1. Full Name OK Question Title * 2. EAACI Number OK Question Title * 3. Which of the following is not true about anaphylaxis treatment? A) Adrenaline should be used as the drug of first choice in the acute management of anaphylaxis B) Adrenaline should be administered by the intramuscular route into the anterolateral aspect of the mid-thigh C) When used prophylactically, adrenaline can reduce severe adverse effects associated with anti-snake venom administration D) Children that weigh more than 30 kgs should be prescribed a 0.3mg adrenaline autoinjector E) In children the maximal plasma concentration of adrenaline occurs quicker with the subcutaneous route than the intramuscular route OK Question Title * 4. According to the “Diagnosis and management of drug‐induced anaphylaxis in children: An EAACI position paper”, which of the following is not true about diagnosis and treatment of drug-induced anaphylaxis in children? A) Drug induced anaphylaxis is very common in children B) For children with positive allergic workup after suspicion of anaphylaxis to a vaccine, the vaccine can still be administered in graded dose according to the protocol proposed by the American Academy of Paediatrics C) Once a diagnosis is established and a specific drug (or drug family) is implicated, a complete avoidance of the drug is the safest choice D) A previous history of an anaphylactic reaction, co‐existent asthma, atopy, and atopic diseases are reported to be major risk factors for anaphylactic reactions in general among both adults and children E) As data on different risk factors in drug-induced anaphylaxis in children are inconsistent and some-times contradicting, this seems to be a field that needs further exploration in future research OK Question Title * 5. According to the EAACI position paper on management of patients with chronic rhinosinusitis (CRS) during the COVID-19 pandemic which of the following is not true? A) According to the current WHO guidelines, patients at risk, or diagnosed with COVID-19, should continue to be treated for all other diseases, if the treatment does not interfere with COVID-19 B) Intranasal corticosteroids are effective in reducing the total symptom score in adults suffering from acute post-viral rhinosinusitis C) The use of intranasal corticosteroids, in the approved doses and indications, leads to an increased risk of SARS-CoV-2 infection or trigger a more severe course of COVID-19 D) Worsening of CRS can trigger exacerbations of asthma, which the WHO also regards as a risk factor for severe courses of COVID-19 disease E) Systemic glucocorticosteroids should be used with caution in CRS in the current COVID-19 pandemic and should be reserved for patients with severe symptoms and in the absence of a therapeutic alternative OK Question Title * 6. According to FDA approvals for biologicals in severe asthma which of the following is not true? A) The recommended posology of Reslizumab is 3mg/kg once every 4 weeks B) The recommended posology of Omalizumab is 75 to 375mg SC every 2 or 4 weeks C) The recommended posology of Mepolizumab is 100mg SC once every 4 weeks D) The recommended posology of Mepolizumab is 100mg IV once every 4 weeks E) Reslizumab is administered by intravenous infusion over 20-50 minutes OK Question Title * 7. Which of the following is not true about possible protective and risk factors for severe and critical ill COVID-19 patients? A) The protective role of Vitamins C and D needs further research B) Severe disease with gastrointestinal symptoms at admission has been shown to have a strong association as a risk factor C) Severe disease with high serum IL-6 levels has a strong association as a risk factor D) The protective role of high-fiber and Ketogonic diet needs more research to assess association E) There are strong associations for severe disease in healthcare workers OK DONE
